pdf   xlsx method abbreviations

glioblastoma (GB), nivolumab alone , meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 1.04 [0.83, 1.30]< 10%1 study (1/-)36.6 %NAnot evaluable crucial-
progression or deaths (PFS) 1.97 [1.57, 2.48]< 10%1 study (1/-)0.0 %NAnot evaluable important-
objective responses (ORR) 0.28 [0.14, 0.57]> 10%1 study (1/-)0.0 %NAnot evaluable non important-

safety endpoints 00

TRAE (any grade) 0.96 [0.63, 1.47]< 10%1 study (1/-)57.3 %NAnot evaluable non important-
TRAE (grade 3-4) 1.24 [0.70, 2.19]< 10%1 study (1/-)22.9 %NAnot evaluable non important-
TRAE leading to death (grade 5) 0.91 [0.02, 45.94]< 10%1 study (1/-)51.9 %NAnot evaluable non important-

TRAE (grade 3-4) endpoints 00

Diarrhoea TRAE (grade 3-4) 0.91 [0.02, 45.94]< 10%1 study (1/-)51.9 %NAnot evaluable non important-
Fatigue TRAE (grade 3-4) 11.22 [0.62, 202.39]< 10%1 study (1/-)5.3 %NAnot evaluable non important-
Headache TRAE (grade 3-4) 3.66 [0.16, 81.65]< 10%1 study (1/-)21.0 %NAnot evaluable non important-
Hypertension TRAE (grade 3-4) 0.03 [0.00, 0.55]< 10%1 study (1/-)99.1 %NAnot evaluable non important-
Increased ALT TRAE (grade 3-4) 7.39 [0.39, 140.92]< 10%1 study (1/-)9.4 %NAnot evaluable non important-
Increased lipase level TRAE (grade 3-4) 7.39 [0.39, 140.92]< 10%1 study (1/-)9.4 %NAnot evaluable non important-
Nausea TRAE (grade 3-4) 0.91 [0.02, 45.94]< 10%1 study (1/-)51.9 %NAnot evaluable non important-
Pneumonitis TRAE (grade 3-4) 3.66 [0.16, 81.65]< 10%1 study (1/-)21.0 %NAnot evaluable non important-
Pruritus TRAE (grade 3-4) 0.91 [0.02, 45.94]< 10%1 study (1/-)51.9 %NAnot evaluable non important-
Rash TRAE (grade 3-4) 0.91 [0.02, 45.94]< 10%1 study (1/-)51.9 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons